PPARγ has emerged as one of the most promising therapeutic targets for cardiovascular complications, and its synthetic ligands (Lim et al., 2015), such as Thiazolidinediones (TZDs) have also been shown to have anti-atherosclerosis function (Viles-Gonzalez et al., 2004; Nakaya et al., 2009). This evidence concerns the gene PPARG and atherosclerosis.